Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth?

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

IPOBIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST__________THIS IS A RESTRICTED ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

It has also been sold in generic form by several other producers, some of which have also been named in litigation, including Boehringer Ingelheim, Pfizer, and Johnson & Johnson. GSK's settlement ...

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...